Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

 Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

Shots:

  • The P-III CHOICE-01 trial evaluates toripalimab + CT vs CT alone in 465 patients in a ratio (2:1) with advanced sq./nonsq. NSCLC without driver mutations
  • The interim analysis met its 1EPs i.e., improvement in PFS, superior ORR & DoR, OS data are still maturing. The safety profile was consistent with PD-1 inhibitor while final PFS & additional interim OS analyses are expected in later 2021
  • The companies plan to discuss with US FDA for submission of toripalimab’s BLA to treat NSCLC. The therapy has received FTD for mucosal melanoma, ODD for NPC, mucosal melanoma & soft tissue sarcoma, BTD for combination therapy as 1L treatment & for monothx. as 2L treatment of recurrent or metastatic NPC

Click here to read full press release/ article | Ref: Globe Newswire | Image: Coherus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post